je.st
news
Orexigen: Contrave Sales Dip, Passing Belviq Still A Few Weeks Away
2015-06-02 19:17:14| Biotech - Topix.net
Many Orexigen investors thought that this may be the week when Contrave outpaced Arena's Belviq in overall sales, but alas, the sales actually lost a bit of ground and that event is likely two or three weeks away. Contrave sales came in at a bit below 13,400 according to IMS health, and Contrave sits about 900 scripts behind the market share leader in Belviq.
Tags: sales
away
weeks
passing
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||